353 related articles for article (PubMed ID: 34321474)
1. IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro.
Prelli Bozzo C; Nchioua R; Volcic M; Koepke L; Krüger J; Schütz D; Heller S; Stürzel CM; Kmiec D; Conzelmann C; Müller J; Zech F; Braun E; Groß R; Wettstein L; Weil T; Weiß J; Diofano F; Rodríguez Alfonso AA; Wiese S; Sauter D; Münch J; Goffinet C; Catanese A; Schön M; Boeckers TM; Stenger S; Sato K; Just S; Kleger A; Sparrer KMJ; Kirchhoff F
Nat Commun; 2021 Jul; 12(1):4584. PubMed ID: 34321474
[TBL] [Abstract][Full Text] [Related]
2. Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.
Zhao X; Sehgal M; Hou Z; Cheng J; Shu S; Wu S; Guo F; Le Marchand SJ; Lin H; Chang J; Guo JT
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263263
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis.
Bayati A; Kumar R; Francis V; McPherson PS
J Biol Chem; 2021; 296():100306. PubMed ID: 33476648
[TBL] [Abstract][Full Text] [Related]
4. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection.
Carlos AJ; Ha DP; Yeh DW; Van Krieken R; Tseng CC; Zhang P; Gill P; Machida K; Lee AS
J Biol Chem; 2021; 296():100759. PubMed ID: 33965375
[TBL] [Abstract][Full Text] [Related]
5. IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms.
Wrensch F; Winkler M; Pöhlmann S
Viruses; 2014 Sep; 6(9):3683-98. PubMed ID: 25256397
[TBL] [Abstract][Full Text] [Related]
6. Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection.
Fuentes-Prior P
J Biol Chem; 2021; 296():100135. PubMed ID: 33268377
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells.
Nchioua R; Schundner A; Kmiec D; Prelli Bozzo C; Zech F; Koepke L; Graf A; Krebs S; Blum H; Frick M; Sparrer KMJ; Kirchhoff F
J Virol; 2022 Jun; 96(11):e0059422. PubMed ID: 35543509
[TBL] [Abstract][Full Text] [Related]
8. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
Choudhury A; Mukherjee S
J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
[TBL] [Abstract][Full Text] [Related]
9. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
10. Opposing activities of IFITM proteins in SARS-CoV-2 infection.
Shi G; Kenney AD; Kudryashova E; Zani A; Zhang L; Lai KK; Hall-Stoodley L; Robinson RT; Kudryashov DS; Compton AA; Yount JS
EMBO J; 2021 Feb; 40(3):e106501. PubMed ID: 33270927
[TBL] [Abstract][Full Text] [Related]
11. The Integral Membrane Protein ZMPSTE24 Protects Cells from SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation.
Shilagardi K; Spear ED; Abraham R; Griffin DE; Michaelis S
mBio; 2022 Oct; 13(5):e0254322. PubMed ID: 36197088
[TBL] [Abstract][Full Text] [Related]
12. The P681H Mutation in the Spike Glycoprotein of the Alpha Variant of SARS-CoV-2 Escapes IFITM Restriction and Is Necessary for Type I Interferon Resistance.
Lista MJ; Winstone H; Wilson HD; Dyer A; Pickering S; Galao RP; De Lorenzo G; Cowton VM; Furnon W; Suarez N; Orton R; Palmarini M; Patel AH; Snell L; Nebbia G; Swanson C; Neil SJD
J Virol; 2022 Dec; 96(23):e0125022. PubMed ID: 36350154
[TBL] [Abstract][Full Text] [Related]
13. Syncytia formation by SARS-CoV-2-infected cells.
Buchrieser J; Dufloo J; Hubert M; Monel B; Planas D; Rajah MM; Planchais C; Porrot F; Guivel-Benhassine F; Van der Werf S; Casartelli N; Mouquet H; Bruel T; Schwartz O
EMBO J; 2020 Dec; 39(23):e106267. PubMed ID: 33051876
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of severe acute respiratory syndrome coronavirus 2 infection.
Ge J; Zhang S; Zhang L; Wang X
Curr Opin HIV AIDS; 2021 Jan; 16(1):74-81. PubMed ID: 33186231
[TBL] [Abstract][Full Text] [Related]
15. ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants.
Ou J; Zhang Y; Wang Y; Zhang Z; Wei H; Yu J; Wang Q; Wang G; Zhang B; Wang C
Signal Transduct Target Ther; 2022 Feb; 7(1):43. PubMed ID: 35140198
[No Abstract] [Full Text] [Related]
16. SARS-CoV-2 Spike protein enhances ACE2 expression via facilitating Interferon effects in bronchial epithelium.
Zhou Y; Wang M; Li Y; Wang P; Zhao P; Yang Z; Wang S; Zhang L; Li Z; Jia K; Zhong C; Li N; Yu Y; Hou J
Immunol Lett; 2021 Sep; 237():33-41. PubMed ID: 34228987
[TBL] [Abstract][Full Text] [Related]
17. The role of microRNAs in modulating SARS-CoV-2 infection in human cells: a systematic review.
Marchi R; Sugita B; Centa A; Fonseca AS; Bortoletto S; Fiorentin K; Ferreira S; Cavalli LR
Infect Genet Evol; 2021 Jul; 91():104832. PubMed ID: 33812037
[TBL] [Abstract][Full Text] [Related]
18. Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions.
Goc A; Sumera W; Rath M; Niedzwiecki A
PLoS One; 2021; 16(6):e0253489. PubMed ID: 34138966
[TBL] [Abstract][Full Text] [Related]
19. An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2.
Williams-Noonan BJ; Todorova N; Kulkarni K; Aguilar MI; Yarovsky I
J Phys Chem B; 2021 Mar; 125(10):2533-2550. PubMed ID: 33657325
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 structural coverage map reveals viral protein assembly, mimicry, and hijacking mechanisms.
O'Donoghue SI; Schafferhans A; Sikta N; Stolte C; Kaur S; Ho BK; Anderson S; Procter JB; Dallago C; Bordin N; Adcock M; Rost B
Mol Syst Biol; 2021 Sep; 17(9):e10079. PubMed ID: 34519429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
